Cancer treatment redefined - tailoring the immune system to fight cancer

Zelluna Immunotherapy is a company dedicated to the development of innovative immunotherapies for the treatment of a broad range of cancers with a high unmet medical need. The company’s core asset consists of a large panel of tumour specific T cell receptors (TCRs) isolated from long-term survivors from cancer vaccine trials that can be used in multiple therapeutic settings.